FindTrial
Sign In

Phase II Study of ME3738 prolonged administration in Chronic Hepatitis C patients.

Phase II Study of ME3738 prolonged administration in Chronic Hepatitis C patients.

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221188
Enrollment
Unknown
Registered
2010-08-06
Start date
2010-08-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis C

Interventions

investigational material(s) Generic name etc : ME3738 INN of investigational material : Therapeutic category code : 639 Other biological preparations Dosage and Administration for Investigational mat

Sponsors

MEIJI SEIKA KAISHA, LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - The patients who are completed 48 weeks administration for the "Phase II Study of ME3738 in Chronic Hepatitis C Patients". etc.

Exclusion criteria

Exclusion criteria: - The patients who exihibited some clinically problemed adverse events. etc.

Design outcomes

Primary

MeasureTime frame
Efficacy and Safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026